People · Operator
Named in public records as an officer, director or promoter · active 2009–2015 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vaxin Inc. | — | Biotechnology | Series C | $50.0M | $1.7B | 2015 |
| DARA BioSciences, Inc. | — | Pharmaceuticals | Seed | $4.6M | $55.1M | 2009 |
David Drutz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Drutz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Florent Gros | 1 | 4 |
| Marten Steen | 1 | 3 |
| Haywood Cochrane | 1 | 2 |
| Philippe Pouletty | 1 | 1 |
| Scot Roberts | 1 | 1 |
| Philip Hodges | 1 | 1 |
| Klaus Schafer | 1 | 1 |
| William Enright | 1 | 1 |
| David D Drutz | 1 | 1 |
| Steve F Gorlin | 1 | 1 |
| Haywood D Cochrane | 1 | 1 |
| Gail F Lieberman | 1 | 1 |
| Christopher F Clement | 1 | 1 |
| Ann A Rosar | 1 | 1 |
| Gail F Liebarman | 1 | 1 |
| Richard A Franco | 1 | 1 |
| Gail Lieberman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.